PMID- 26463602
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20181202
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 95
IP  - 20
DP  - 2015 May 26
TI  - [Effects of rare islet autoantibodies on islet function in patients with latent 
      autoimmune diabetes in adults].
PG  - 1563-7
AB  - OBJECTIVE: To observe the changes of islet function in ZnT8A positive and IA-2A 
      positive patients so as to provide rationales for early intervention of LADA 
      patients. METHODS: A total of 69 outpatients and inpatients with newly diagnosed 
      LADA testing for GADA, IA-2A and ZnT8A by radioligand binding assay (RBA) were 
      enrolled from 2005 to 2010, including 13 with double positive for GADA and ZnT8A 
      (GADA+ZnT8A double positive group), 14 with double positive for GADA and IA-2A 
      (GADA+IA-2A double positive group) and 42 with positive for GADA alone (GADA 
      positive group), 40 type 2 diabetes mellitus (T2DM) patients negative for the 
      above three autoantibodies were selected as control subjects (T2DM group). The 
      baseline clinical data of all groups were compared and all patients were followed 
      annually for 3 years. Fasting plasma glucose (FBG), HbA1c, fasting C-peptide 
      (FCP), C-peptide 2 h after meal (2 h CP), triglyceride (TG), total cholesterol 
      (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein 
      cholesterol (LDL-C) were detected and compared among the above groups during the 
      follow-ups. RESULTS: Compared to GADA positive group and T2DM group, the 
      GADA+IA-2A double positive group had higher level of baseline FBG and HbA1c (10.5 
      +/- 3.6) mmol/L and (9.3 +/- 2.6) % vs (9.2 +/- 2.0) mmol/L and (7.4 +/- 2.0) %, P = 
      0.017, 0.011) and had lower level of baseline FCP (415 (68-934) vs 538 (224-1 
      146) and 643 (163-1 658) pmol/L, P = 0.015, 0.003). During the follow-ups, FCP 
      decreased year-on-year in GADA+ZnT8A double positive, GADA+IA-2A double positive 
      and GADA positive groups. The annual average rate of decrease in FCP was more 
      rapid in GADA+ZnT8A double positive and GADA+IA-2A double positive groups than 
      those in GADA positive alone and T2DM groups (all P < 0.01). CONCLUSIONS: The 
      islet functions of newly diagnosed LADA patients with GADA and IA-2A positive are 
      much worse. And emergence of ZnT8A and IA-2A may accelerate the failure of islet 
      function with diabetic progress in LADA patients.
FAU - Huang, Gan
AU  - Huang G
AD  - Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya 
      Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central 
      South University, Changsha 410011, China.
FAU - Sun, Guizhong
AU  - Sun G
AD  - Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya 
      Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central 
      South University, Changsha 410011, China.
FAU - Yang, Lin
AU  - Yang L
AD  - Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya 
      Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central 
      South University, Changsha 410011, China.
FAU - Li, Xia
AU  - Li X
AD  - Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya 
      Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central 
      South University, Changsha 410011, China.
FAU - Xiang, Yufei
AU  - Xiang Y
AD  - Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya 
      Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central 
      South University, Changsha 410011, China.
FAU - Zhou, Zhiguang
AU  - Zhou Z
AD  - Diabetes Center, Institute of Metabolism & Endocrinology, Second Xiangya 
      Hospital, Key Laboratory of Diabetes Immunology, Ministry of Education, Central 
      South University, Changsha 410011, China; Email: zhouzg@hotmail.com.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Autoantibodies)
RN  - EC 4.1.1.15 (Glutamate Decarboxylase)
SB  - IM
MH  - Adult
MH  - Autoantibodies
MH  - *Diabetes Mellitus, Type 1
MH  - Diabetes Mellitus, Type 2
MH  - Glucose Intolerance
MH  - Glutamate Decarboxylase
MH  - Humans
MH  - *Islets of Langerhans
EDAT- 2015/10/16 06:00
MHDA- 2015/10/31 06:00
CRDT- 2015/10/15 06:00
PHST- 2015/10/15 06:00 [entrez]
PHST- 2015/10/16 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2015 May 26;95(20):1563-7.